Synendos Therapeutics takes in Series A

Synendos Therapeutics, a Swiss biopharmaceutical company focused on treating central nervous system disorders, has raised CHF 20 million (almost $22 million) in Series A financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this